Skip to main content

Urethral Bulking Agents

Urethral bulking improves mucosal coaptation by injecting material into the urethral wall. It offers a less invasive option for women with stress urinary incontinence (SUI) who prioritize a shorter procedure or wish to avoid more invasive surgery. Repeat injections and subsequent continence surgery may be needed. Improvement is more common than durable complete dryness.[1]

This page addresses selection and procedural decisions. Product composition, labeling and device details belong in the Bulkamid, Macroplastique and other device pages. See Female SUI for the evaluation and treatment pathway.

Patient selection​

SituationDecision
Patient prefers a less invasive procedure or declines meshDiscuss bulking alongside nonmesh surgery and nonsurgical options; lower procedural burden comes with a lower chance of dryness
Anesthetic risk or frailtyLocal-anesthetic treatment may be feasible, but plan for retention, infection and reliable access to follow-up
Recurrent SUI after a slingEstablish the cause of leakage and assess for obstruction or mesh complications before adding outlet resistance
Fixed, poorly mobile urethraBulking is an option, but AUA/SUFU favors autologous pubovaginal sling in this particular setting; ISD does not make bulking automatically preferable
Mixed symptoms or incomplete emptyingSeparate stress leakage from urgency and voiding dysfunction before choosing an outlet procedure

These decisions require individualized counseling; the AUA/SUFU guideline does not identify one universally preferred injectable agent.[1]

For Bulkamid specifically, the US indication is SUI due to ISD in adult women with SUI or stress-predominant mixed incontinence. The current manufacturer summary contraindicates acute UTI and warns against use before correction of urethral/bladder-neck strictures. It also lists populations in which safety/effectiveness has not been established, including substantial urethral hypermobility, neurogenic bladder, detrusor overactivity and BMI above 35 kg/m². These evidence limitations should not be silently equated with proven safety or reclassified as absolute contraindications.[2]

Review prior bulking products and injection sites. Bulkamid labeling advises against injecting a site previously treated with another agent, or placing another agent into a Bulkamid-treated site. It also warns not to use Bulkamid in men.[2]

Procedural workflow​

Use the exact product's current instructions and training. Needle, access system, injection depth, location and volume differ between agents; an interchangeable clock-face recipe is inappropriate.

  1. Confirm the stress-leakage target, baseline emptying and relevant prior procedures. Test urine and treat infection before injection.
  2. Review anticoagulants and bleeding risk with the prescribing team; a short office procedure does not eliminate hematoma risk. Choose an anesthesia plan and antimicrobial prophylaxis according to the product and local protocol.
  3. Inspect the urethra and bladder and confirm tissue suitability before injection.
  4. For endoscopically administered systems, place deposits under direct vision in the product-specified plane, aiming for coaptation while preserving perfusion. Follow the exact instructions for other delivery systems.
  5. With Bulkamid, stop if superficial mucosal capillaries fade; avoid intravascular injection, damaged tissue and overcorrection that can obstruct the outlet.
  6. Empty the bladder with an appropriate soft catheter when needed, avoiding disruption of the deposits.
  7. Assess voiding and residual urine before discharge. Give a clear retention-management and urgent-contact plan.[3][2]

The January 2020 FDA-hosted Bulkamid IFU specifies a maximum 2 mL per treatment session, top-up at least four weeks later, and evidence for up to three sessions. Those are version-specific instructions, not an unlimited reinjection schedule or a universal dose for other agents. Confirm the current IFU supplied with the device; the currently posted manufacturer summary references a later revision.[3][2]

Efficacy and the most useful comparison​

Five-year randomized PAHG versus TVT trial​

The Helsinki noninferiority trial randomized 223 women; 212 received the assigned treatment and 195 attended five-year follow-up. High satisfaction (score at least 80/100) occurred in 74/99 PAHG recipients (74.7%) and 89/96 TVT recipients (92.7%). The difference was 18.0 percentage points (95% CI 7.7–28.0); PAHG did not meet the prespecified 20-point noninferiority margin.[4]

Perioperative or postoperative complications before crossover were reported in 22/99 (22.2%) after PAHG and 42/96 (43.8%) after TVT. These are not rates of severe complications or reoperation alone. This trial supports a counseling tradeoff between higher satisfaction with TVT and fewer recorded complications with PAHG; satisfaction is not interchangeable with objective dryness.[4]

Other evidence​

The 2017 Cochrane review included 14 trials and 2,004 women, but its reported search date was November 2010. It found limited and heterogeneous evidence, generally greater improvement with surgery, and no reliable ranking of agents or injection locations. It should be read alongside later trials rather than treated as a current comprehensive comparison.[5]

A later six-study meta-analysis (710 patients) also favored surgery for subjective improvement (bulking-versus-surgery RR 0.70, 95% CI 0.53–0.92). Its complication estimate was imprecise (RR 1.30, 95% CI 0.30–5.66), so absence of a statistically significant difference does not establish equal safety.[6]

Longer-term observational data support persistence of benefit for some women. Brosche's single-center series included 388 seven-year completers from 1,200 treated patients; 67.1% of those receiving PAHG as their primary procedure reported cure or improvement, and 19.5% underwent another continence procedure. This is not a seven-year cure rate in an unselected cohort. Its 15.3% report of prolonged emptying time should not be relabeled acute urinary retention.[7]

Recurrent SUI after a sling​

Bulking may suit a patient who has persistent stress leakage and wishes to avoid further dissection. An 11-study review reported a pooled 75% cure-or-improvement estimate, with substantial heterogeneity. Separate Macroplastique and Bulkamid subgroup estimates are not randomized head-to-head evidence and should not determine a product ranking.[8]

Persistent urgency, obstruction, urethral erosion, fistula or other structural complications require their own treatment. A later sling or other reconstruction may remain possible, but an injected permanent material must be documented for future surgery. Do not promise that every later operation is unaffected by prior injection.[1][3]

Safety and follow-up​

Discuss dysuria, hematuria, infection, pain, transient retention, persistent obstruction, new urgency and treatment failure. Agent-specific problems include erosion, extrusion, granuloma and migration. The absence of reported PAHG erosion or migration in an older systematic review does not establish that these events are impossible; current labeling includes them among potential adverse events.[9][2]

After discharge, inability to void, worsening pain, fever or substantial bleeding warrants prompt assessment. Reassess persistent leakage before repeating treatment: the target may be residual SUI, urgency, incomplete emptying or another problem. Record the material, lot, volume, location and date so later clinicians can interpret cystoscopy or imaging correctly.[3]

Vaginal estrogen may be appropriate for a separate GSM indication; it is not a proven required preparation that makes bulking effective. Vaginal/topical estrogen and duloxetine have separate indications and jurisdiction-specific considerations.

Men and investigational injections​

The AUA/GURS/SUFU 2024 guideline advises men with incontinence after prostate treatment that bulking has low efficacy and rarely achieves cure. Selected patients unable or unwilling to undergo more effective treatment may discuss appropriately scoped alternatives, but female PAHG results must not be extrapolated to men. Bulkamid's warning against male use still applies.[10][2]

Male slings and AUS are separate surgical pathways. Regenerative cell injections remain investigational and should not be presented as an established alternative with efficacy equivalent to approved bulking treatment.[1]

Device and treatment references​

References​

1. Kobashi KC, Vasavada S, Bloschichak A, et al. "Updates to Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline (2023)." J Urol. 2023;209(6):1091-1098. doi:10.1097/JU.0000000000003435

2. Boston Scientific. Bulkamid Urethral Bulking System: current US indications, safety and warnings summary, referencing IFU110-0303rB. Manufacturer safety summary.

3. Contura / US Food and Drug Administration. Bulkamid Urethral Bulking System: Instructions for Use,10078-001, January2020. FDA physician labeling.

4. Itkonen Freitas AM, Isaksson C, Rahkola-Soisalo P, Mentula M, Mikkola TS. Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Injection for Stress Urinary Incontinence — 5-Year Follow-Up. NEJM Evid. 2025;4(5):EVIDoa2400216. doi:10.1056/EVIDoa2400216.

5. Kirchin V, Page T, Keegan PE, et al. "Urethral Injection Therapy for Urinary Incontinence in Women." Cochrane Database Syst Rev. 2017;7:CD003881. doi:10.1002/14651858.CD003881.pub4

6. Pivazyan L, Kasyan G, Grigoryan B, Pushkar D. "Effectiveness and Safety of Bulking Agents Versus Surgical Methods in Women With Stress Urinary Incontinence: A Systematic Review and Meta-analysis." Int Urogynecol J. 2022;33(4):777-787. doi:10.1007/s00192-021-04937-1

7. Brosche T, Kuhn A, Lobodasch K, Sokol ER. "Seven-year Efficacy and Safety Outcomes of Bulkamid for the Treatment of Stress Urinary Incontinence." Neurourol Urodyn. 2021;40(1):502-508. doi:10.1002/nau.24589

8. Braga A, Caccia G, Papadia A, et al. "Urethral Bulking Agents for the Treatment of Recurrent Stress Urinary Incontinence: A Systematic Review and Meta-analysis." Maturitas. 2022;163:28-37. doi:10.1016/j.maturitas.2022.05.007

9. Hoe V, Haller B, Yao HH, O'Connell HE. "Urethral Bulking Agents for the Treatment of Stress Urinary Incontinence in Women: A Systematic Review." Neurourol Urodyn. 2021;40(6):1349-1388. doi:10.1002/nau.24696

10. American Urological Association / GURS / SUFU. Incontinence After Prostate Treatment Guideline. Amended2024. Statement25 and discussion. Guideline.